ReviewNeuropsychiatric disease and treatment2013
Levodopa-induced dyskinesias in Parkinson's disease: emerging treatments.
Review in Neuropsychiatric disease and treatment, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 45 citations in OpenAlex.
- Implication of regional selectivity of dopamine deficits in impaired suppressing of involuntary movements in Parkinson's disease.Neuroscience and biobehavioral reviews · 2024Review
- Tyrosine Hydroxylase Inhibitors and Dopamine Receptor Agonists Combination Therapy for Parkinson's Disease.International journal of molecular sciences · 2024Review
- The multifaceted functions of β-arrestins and their therapeutic potential in neurodegenerative diseases.Experimental & molecular medicine · 2024Review
- Effect of kaempferol on the transgenic Drosophila model of Parkinson's disease.Scientific reports · 2020Article
- Advances in treatment of neurodegenerative diseases: Perspectives for combination of stem cells with neurotrophic factors.World journal of stem cells · 2020Review
- Levodopa/Benserazide PLGA Microsphere Prevents L-Dopa-Induced DyskinesiaFrontiers in pharmacology · 2019Article
- Physiological and Functional Basis of Dopamine Receptors and Their Role in Neurogenesis: Possible Implication for Parkinson's disease.Journal of experimental neuroscience · 2018Article
- Botulinum Neurotoxin A Injected Ipsilaterally or Contralaterally into the Striatum in the Rat 6-OHDA Model of Unilateral Parkinson's Disease Differently Affects Behavior.Frontiers in behavioral neuroscience · 2017Article
- Review
- Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation.Molecular neurodegeneration · 2016Article
- Neuroprotective Effects of A Standardized Flavonoid Extract of Safflower Against Neurotoxin-Induced Cellular and Animal Models of Parkinson's Disease.Scientific reports · 2016Article
- Levodopa-Induced Dyskinesia Is Related to Indirect Pathway Medium Spiny Neuron Excitotoxicity: A Hypothesis Based on an Unexpected Finding.Parkinson's disease · 2016Review
- Amelioration of L-Dopa-Associated Dyskinesias with Triterpenoic Acid in a Parkinsonian Rat Model.Neurotoxicity research · 2016Article
- Assessment of Parkinson's disease levodopa-induced dyskinesia: a qualitative research study.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2015Article
- The neuroprotective potential of sinapic acid in the 6-hydroxydopamine-induced hemi-parkinsonian rat.Metabolic brain disease · 2015Article
- Presynaptic effects of levodopa and their possible role in dyskinesia.Movement disorders : official journal of the Movement Disorder Society · 2015Review
- Sustained increase of PKA activity in the postcommissural putamen of dyskinetic monkeys.Molecular neurobiology · 2014Article
- Eryptosis as a marker of Parkinson's disease.Aging · 2014Article
- Treatment of advanced Parkinson's disease.Current opinion in neurology · 2014Review
- Use of genetically modified mesenchymal stem cells to treat neurodegenerative diseases.International journal of molecular sciences · 2014Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Parkinson's disease therapy is still focused on the use of L-3,4-dihydroxyphenylalanine (levodopa or L-dopa) for the symptomatic treatment of the main clinical features of the disease, despite intensive pharmacological research in the last few decades. However, regardless of its effectiveness, the long-term use of levodopa causes, in combination with disease progression, the development of motor complications termed levodopa-induced dyskinesias (LIDs). LIDs are the result of profound modifications in the functional organization of the basal ganglia circuitry, possibly related to the chronic and pulsatile stimulation of striatal dopaminergic receptors by levodopa. Hence, for decades the key feature of a potentially effective agent against LIDs has been its ability to ensure more continuous dopaminergic stimulation in the brain. The growing knowledge regarding the pathophysiology of LIDs and the increasing evidence on involvement of nondopaminergic systems raises the possibility of more promising therapeutic approaches in the future. In the current review, we focus on novel therapies for LIDs in Parkinson's disease, based mainly on agents that interfere with glutamatergic, serotonergic, adenosine, adrenergic, and cholinergic neurotransmission that are currently in testing or clinical development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.